Apogee Therapeutics
APGE
174 hedge funds and large institutions have $2.37B invested in Apogee Therapeutics in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 33 closing their positions.
143% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $5.26M
3.62% more ownership
Funds ownership: 125.6% → 129.22% (+3.6%)
9% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 57
4% less funds holding
Funds holding: 182 → 174 (-8)
6% less capital invested
Capital invested by funds: $2.51B → $2.37B (-$144M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
21% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$26.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$25.7M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$21.5M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$53.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$40.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$31M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$25.8M |
| 5 |
Jennison Associates
New York
|
-$11.7M |
APGE Hedge Fund Activity: Q3 2025 in Review
174 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q3 2025, worth a combined $2.37B — down 5.7% from $2.51B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of APGE and 26 opened new positions — a net loss of 7 holders — while 57 trimmed existing stakes and 62 added.
The largest buyer was Wellington Management Group, adding an estimated $35.1M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $53.4M sold.
- 174 institutional investors held Apogee Therapeutics (APGE) as of Q3 2025, down from 182 in Q2 2025.
- Funds reported $2.37B of Apogee Therapeutics stock for Q3 2025, down 5.7% quarter-over-quarter.
- 26 funds opened new Apogee Therapeutics positions in Q3 2025 and 33 closed out, a net change of -7 holders.
- The largest Apogee Therapeutics buyer in Q3 2025 was Wellington Management Group, an estimated $35.1M added.
- The largest Apogee Therapeutics seller in Q3 2025 was Point72 Asset Management, an estimated $53.4M sold.
Based on aggregated 13F filings for Q3 2025.